West Virginia Clinical Trials Report — July 2026

West Virginians considering a clinical trial should check eligibility soon: 13 recruiting studies are expected to close within the next 90 days. Two of those studies accept healthy volunteers, creating a limited window for people without a diagnosed condition. Across the state, 320 trials are currently recruiting through 158 research sites in 23 cities.

July brought 3 new trials, a sharp decline from 9 in June and the lowest monthly total since April. The six-month pattern has been uneven: 8 new trials opened in February, followed by 4 in March, 3 in April, 1 in May, 9 in June, and 3 in July. That fluctuation makes the studies opening now, and those approaching closure, especially important for people actively seeking a match.

Enrollment deadlines are approaching across several conditions

The closing-soon list covers a broad range of health concerns, rather than concentrating in one disease area. Patients with Alzheimer disease, chronic kidney disease, iron deficiency anemia, chronic low back pain, atopic dermatitis, atrial fibrillation, bleeding disorders, or anterior cruciate ligament rupture may find relevant studies, but should begin screening promptly because eligibility checks can take time.

• Alzheimer disease, anterior cruciate ligament rupture, atopic dermatitis, atrial fibrillation, and bleeding — 1 closing-soon trial each
• Chronic kidney disease and iron deficiency anemia — 1
• Chronic low back pain — 1
• Chronic migraine in children — 1
• Infant behavior and infant development — 1 each

The available data identify 2 closing-soon trials that accept healthy volunteers, but do not specify which conditions they address. Healthy adults should review those opportunities now rather than waiting for another monthly update. Trial listings can change before the projected closing date, so prospective participants should confirm that enrollment remains open with the research site.

A major Phase 3 lung cancer study leads July’s new openings

The most prominent new study is Bristol-Myers Squibb’s Phase 3 trial NCT07680790, titled “Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02).” The study plans to enroll 850 participants with previously untreated, locally advanced or metastatic EGFR-mutant non-small cell lung cancer.

Researchers will compare izalontamab brengitecan, also called iza-bren, combined with osimertinib against osimertinib alone or osimertinib combined with platinum-based chemotherapy. As a major-sponsor Phase 3 drug study, it may attract people seeking an advanced treatment option for a specific molecular form of lung cancer. Eligibility will depend on cancer characteristics, prior treatment history, overall health, and the participating site.

• NCT07680790 — Bristol-Myers Squibb Phase 3 study of izalontamab brengitecan combinations for previously untreated EGFR-mutant non-small cell lung cancer; planned enrollment is 850.
• The other July openings address dementia and knee injury, expanding the month’s options beyond oncology.

The three new studies represent different research approaches: 1 drug trial, 1 device study, and 1 behavioral trial. This gives prospective participants choices that are not limited to experimental medicines. The new conditions are dementia, knee injury, and non-small cell lung cancer, with 1 trial in each area.

Morgantown and Huntington anchor new activity

New trial activity is concentrated in two West Virginia research centers. Morgantown opened 2 of July’s 3 new trials, while Huntington opened 1. Morgantown’s activity is consistent with its role as a major academic and medical hub, while Huntington provides another important access point in the western part of the state.

• Morgantown — 2 new trials
• Huntington — 1 new trial
• Statewide — 320 recruiting trials across 23 cities and 158 sites

The distribution suggests that newly opened research is clustered around established medical centers rather than evenly spread across West Virginia. However, the broader recruiting network reaches 23 cities, so patients should search statewide when a condition has few local options. A study may have multiple locations nationally while offering only one West Virginia site, making travel distance an important part of the decision.

Healthy adults and older adults have opportunities, but few new openings

Only 1 of July’s 3 new trials accepts healthy volunteers, compared with 20 healthy-volunteer trials recruiting statewide overall. People without a medical diagnosis therefore have more options in the existing trial pool than among this month’s openings, including the 2 closing-soon studies that accept healthy participants.

No July new trials include children, and none are limited to female-only or male-only participants. Two new studies include older adults in their eligibility criteria. Older people interested in dementia research or other age-related studies should review the full eligibility requirements, including age ranges and any restrictions involving medications or existing conditions.

The new-trial sponsor mix includes Bristol-Myers Squibb, Marshall University, and West Virginia University. One study is classified as industry-sponsored and 2 fall into the “other” sponsor category, reflecting a combination of commercial and university-linked research. Sponsor involvement can help prospective participants understand who is conducting the study, while the study site remains the best source for questions about visits, procedures, compensation, and screening.

Patients affected by the conditions on the closing-soon list should act first, especially those considering Alzheimer disease, atrial fibrillation, chronic kidney disease, chronic low back pain, or skin disease trials. Healthy adults should check the two time-sensitive volunteer studies as well as the 20 statewide recruiting opportunities. With activity currently centered in Morgantown and Huntington, additional openings later in 2026 could broaden access to residents in other West Virginia communities.